Triple Drug Combo for Advanced Breast Cancer Hits Targets but Falls Short of Standard Care

Hormone receptor-positive, HER2-negative breast cancer remains the most common molecular subtype of the disease, accounting for an estimated 65 to 75 percent of all breast cancer cases diagnosed worldwide. Over the past decade, the introduction of cyclin-dependent kinase 4 and 6 inhibitors has transformed the first-line treatment landscape for patients with advanced forms of this subtype, substantially extending progression-free survival when combined with endocrine therapy. Yet a persistent and troubling reality shadows this progress: a substantial proportion of patients, reported in some analyses to be as high as 60 percent, derive no meaningful clinical benefit from CDK4/6 inhibitors. Resistance, whether intrinsic or acquired, continues to limit the durability of response and leaves clinicians with few evidence-based options for their patients. This unmet need has driven a wave of clinical investigation into rational combination strategies that might deepen or extend the activity of endocrine therapy plus targeted agents.

One such strategy rests on a compelling preclinical rationale. Laboratory studies have suggested that angiogenesis inhibitors, drugs that starve tumors of their blood supply by blocking vascular signaling pathways, may act synergistically with CDK4/6 inhibitors when the two classes are combined. The biological logic is attractive: vascular normalization and CDK4/6 blockade could, in theory, cooperate to suppress tumor growth more effectively than either approach alone. However, translating preclinical synergy into clinical benefit has historically proven difficult in oncology, and clinical data on this particular combination remained sparse. To address that evidence gap, a team of Chinese investigators designed an early-phase trial to test whether adding an angiogenesis inhibitor to the established backbone of a CDK4/6 inhibitor plus fulvestrant, a selective estrogen receptor degrader, could deliver superior outcomes for patients with hormone receptor-positive, HER2-negative advanced breast cancer.

The study, led by Dr. Min Yan of the Department of Breast Disease at Henan Cancer Hospital and The Affiliated Cancer Hospital of Zhengzhou University, was an investigator-initiated, single-center, open-label phase Ib/II trial evaluating the triple combination of famitinib, a multitargeted antiangiogenic tyrosine kinase inhibitor, dalpiciclib, a domestically developed CDK4/6 inhibitor, and fulvestrant. “Although preclinical evidence supports synergistic effects between antiangiogenic therapies and CDK4/6 inhibitors, clinical data on this combination remain limited,” Dr. Yan noted, explaining the motivation for the study. “We therefore initiated this trial to determine whether this regimen could address the substantial unmet clinical needs of the target patient population.” The findings were published online in the Chinese Medical Journal on July 7, 2026, and they offer a sobering, carefully documented lesson in the challenges of modern combination drug development.

A total of 46 eligible patients were enrolled across the two study phases. The trial began with a dose-finding phase Ib component involving 18 patients, in which the investigators systematically escalated and evaluated the tolerability of the three-drug regimen. This work established a recommended phase II dose of famitinib 10 milligrams daily combined with dalpiciclib 100 milligrams daily, administered alongside standard fulvestrant. That the dose of dalpiciclib had to be set at 100 milligrams, at the lower end of its commonly used range, foreshadowed the tolerability issues that would later dominate the safety picture. The phase II portion then enrolled 28 additional patients to assess the antitumor activity of the combination at the established dose.

The initial efficacy signals were, on their face, encouraging. In the phase II cohort, the confirmed objective response rate reached 51.9 percent, meaning that more than half of the evaluable patients experienced measurable tumor shrinkage, while the disease control rate stood at 92.6 percent, indicating that the vast majority of patients achieved at least stable disease. These figures satisfied the prespecified efficacy threshold for the first-stage analysis, and the response rate was numerically higher than benchmarks typically reported for standard first-line regimens in comparable populations. Had the trial stopped there, the narrative might have been one of cautious optimism for a new frontline option in this common breast cancer subtype.

But progression-free survival, the metric that ultimately determines whether a regimen changes clinical practice, told a different story. The median progression-free survival in the phase II cohort was 15.7 months, which failed to demonstrate any advantage over currently available standard first-line treatments. For context, the CDK4/6 inhibitor ribociclib combined with fulvestrant has shown a median progression-free survival of 20.5 months in similar patient populations, nearly five months longer than the triple combination achieved. “The ORR observed in our trial was numerically higher, but this did not translate into a longer PFS,” Dr. Yan explained. “This may be attributable to the high rate of dose reductions necessitated by adverse events, which likely compromised dose intensity and long-term efficacy.” In other words, the regimen may have been biologically active, but patients could not tolerate it at full intensity long enough for that activity to translate into durable disease control.

The safety analysis laid bare the central problem. The most common grade 3 or higher treatment-related adverse events were hematologic, meaning they affected blood cell counts. Decreased neutrophil counts, a condition known as neutropenia that increases susceptibility to serious infections, occurred in 96.4 percent of patients at grade 3 or worse. Decreased leukocyte counts affected 75.0 percent of patients, and decreased platelet counts, which impair blood clotting, were observed in 10.7 percent. Nearly every patient in the trial required a dose reduction because of adverse events. The investigators concluded that the addition of famitinib exacerbated hematologic toxicities beyond levels seen with either agent alone, forcing the frequent dose reductions that likely undermined the regimen’s long-term efficacy. They speculated that a potential pharmacokinetic culprit was a CYP3A4-mediated drug-drug interaction between famitinib and dalpiciclib, since CYP3A4 is a liver enzyme responsible for metabolizing many drugs, and inhibition of this pathway by famitinib could have elevated dalpiciclib exposure and intensified its bone marrow suppression.

The trial also incorporated exploratory biomarker analyses aimed at identifying which patients might benefit most from the combination. These analyses examined outcomes according to mutation status for PIK3CA, a gene frequently altered in hormone receptor-positive breast cancer and a validated therapeutic target, and for BRCA1/2, the well-known DNA repair genes. The results did not reveal statistically significant differences in outcomes based on either mutation status, although patients carrying PIK3CA or BRCA1/2 mutations did show numerically shorter progression-free survival compared with those whose tumors were wild-type at these loci. Given the small sample size, these exploratory findings are hypothesis-generating at best, but they provide useful signals for future studies attempting to define biomarker-selected populations for antiangiogenic combinations.

Following a comprehensive benefit-risk assessment, the investigators made the decision to terminate patient enrollment early. The combination of significant hematologic toxicity, near-universal dose reductions, and the absence of clear superiority over established standard therapies meant that continuing the trial could not be justified for the patient population it was designed to serve. This early termination, while disappointing, reflects the scientific integrity of the trial design: the study was built to detect whether the triple regimen offered genuine clinical advantage, and when that advantage failed to materialize, the responsible course was to stop rather than expose additional patients to a more toxic regimen without proven benefit. Such transparent reporting of negative and ambiguous results remains essential to the rational evolution of combination strategies in oncology.

Despite the outcome, Dr. Yan and her colleagues believe the study yields important forward-looking insights. “Our findings suggest that angiogenesis inhibitors may not represent a preferred option in the frontline treatment of HR+/HER2− breast cancer, but they may have greater potential in more aggressive subtypes like triple-negative breast cancer or refractory disease,” Dr. Yan concluded. This reframing positions antiangiogenic therapy not as a failed class, but as a strategy whose value may lie elsewhere in the breast cancer spectrum, where treatment options are thinner and tumor biology is more dependent on vascular signaling. The researchers also hope the study will inform future clinical trial design, underscoring two enduring principles of oncology drug development: combination strategies must be built on rigorous attention to pharmacokinetic interactions and dose intensity, and patient selection must be grounded in biology rather than convenience. The trial was supported by a grant from the XINRUI Project of Cancer Supportive Care and Treatment Research, with famitinib and dalpiciclib supplied by Jiangsu Hengrui Pharmaceuticals and fulvestrant provided by Chia Tai Tianqing Pharmaceutical Group. For patients with hormone receptor-positive, HER2-negative advanced breast cancer, standard first-line CDK4/6 inhibitor plus endocrine therapy regimens remain the benchmark against which all new combinations must now be measured.

Subject of Research: A phase Ib/II trial of famitinib plus dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast cancer

Article Title: Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer

Article References: Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, HR-positive HER2-negative, CDK4/6 inhibitors, dalpiciclib, famitinib, fulvestrant, angiogenesis inhibitors, progression-free survival, hematologic toxicity, drug-drug interaction, CYP3A4, phase Ib/II trial